Enovis (NYSE:ENOV) Trading Down 4.2% – Time to Sell?

Shares of Enovis Corporation (NYSE:ENOV) traded down 4.2% during mid-day trading on Thursday . The stock traded as low as $21.17 and last traded at $21.0550. 73,497 shares were traded during trading, a decline of 93% from the average session volume of 1,042,203 shares. The stock had previously closed at $21.97.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. William Blair assumed coverage on shares of Enovis in a research note on Friday, April 17th. They set an “outperform” rating on the stock. Needham & Company LLC increased their target price on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Evercore reissued an “outperform” rating and set a $36.00 target price on shares of Enovis in a research note on Friday, May 8th. Finally, BTIG Research reissued a “buy” rating and set a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Enovis Price Performance

The stock has a market capitalization of $1.25 billion, a PE ratio of -1.09 and a beta of 1.38. The stock’s 50 day moving average is $24.03 and its two-hundred day moving average is $24.60. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. Enovis’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company posted $0.81 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arax Advisory Partners purchased a new position in Enovis in the 4th quarter valued at about $29,000. EverSource Wealth Advisors LLC lifted its stake in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after buying an additional 707 shares in the last quarter. GAMMA Investing LLC lifted its stake in Enovis by 353.5% in the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after buying an additional 1,446 shares in the last quarter. Danske Bank A S purchased a new position in Enovis in the 3rd quarter valued at about $64,000. Finally, iSAM Funds UK Ltd acquired a new stake in Enovis in the 3rd quarter valued at about $80,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.